This article refers to:
Yiu ZZ, Warren RB. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. Expert Opin Investig Drugs. 2017 Jan 1:1-7. Available from http://dx.doi.org/10.1080/13543784.2017.1274734
When the above article was first published online, part of the funding text was omitted. This has now been added to both the online and print versions of the article, and has also been included below.
The author apologizes for this error.
Additional information
Funding
ZZN Yiu is funded by a National Institute for Health Research (NIHR) Doctoral Research Fellowship (Ref no: DRF-2015-08-089). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health